

September 14, 2007



Oculus Innovative Sciences to Conduct Conference Call Update on Phase II Study of Microcyn(R) Technology in Mildly Infected Diabetic Foot Ulcers

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced that President and CEO Hoji Alimi will hold a conference call on Monday, September 17, 2007 at 9:00 a.m. (EDT) to update investors on recent progress in the ongoing, open-label Phase II clinical trial of the company's flagship product manufactured using Microcyn(R) Technology in patients with mildly infected diabetic foot ulcers. Oculus plans to highlight feedback from a meeting with prospective Phase III investigators scheduled to take place during the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. The purpose of the meeting is to review general clinical background on Microcyn including study design from the ongoing three-arm open Phase II study. During the call, Mr. Alimi will also comment on Phase II enrollment and plans for the clinical program going forward.

To participate in the conference call, please call 1-877-407-4018 (domestic/toll-free) or 1-201-689-8471 (international). A telephone replay will be available for 48 hours after the call at 1-877-660-6853 (domestic/toll-free), or 1-201-612-7415 (international). Please enter account number 3055 and conference identification number 255635.

About the Trial

Sixteen U.S. medical centers and clinics are currently recruiting for the 60-patient, randomized and open-label Phase II clinical study to evaluate the preliminary safety and efficacy of Microcyn Technology versus systemic oral antibiotics for the treatment of mildly infected diabetic foot infections. The primary efficacy endpoint of the trial is clinical cure or improvement of infection. This study is designed as a proof of concept that Microcyn Technology can induce clinical cure in mildly infected diabetic wounds similar to an antibiotic arm.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is capable of producing a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated wound healing in chronic and acute wounds. It has been

commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.

Oculus' principal operations are in Petaluma, California, and operations are also conducted in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, some matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about our ability to replicate the results of the test in clinical trials, if at all, or for such trials or other tests to establish the conclusions suggested by the results of the test. These forward-looking statements are identified by the use of words such as "comment" "intended," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, risks that revenues will not reach expected levels, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended March 31, 2007 and Form 10-K for the fiscal year ended March 31, 2007. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.

Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.

Source: Oculus Innovative Sciences, Inc.